Indivior Pharmaceuticals, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Indivior Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2023
FY2023
FY2024
FY2025
Revenue
791
901
1,093
1,188
1,239
Cost of revenue
127
151
174
231
246
Gross profit
664
749
919
957
994
Research and development
52
74
116
107
97
Selling, general and administrative
431
469
565
612
634
Operating expenses
831
1,072
919
Operating income
213
-81
-152
38
262
Interest expense
27
27
35
41
45
Interest income
4
19
43
23
22
Pre-tax income
190
-89
-145
20
239
Income tax
-15
-44
-19
13
29
Net income
205
-44
-126
7
210
EBITDA
-65
-137
54
272
EPS, basic
-0.32
-0.92
0.05
1.68
EPS, diluted
-0.32
-0.92
0.05
1.64
Shares, basic (weighted)
139
137
132
125
Shares, diluted (weighted)
139
137
133
128
Balance sheet
FY2021
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
1,102
774
316
319
195
Short-term investments
94
1
0
Receivables
254
254
253
Inventory
95
114
126
167
153
Other current assets
52
21
16
Total current assets
1,444
1,259
1,257
827
652
Property, plant and equipment
58
54
84
100
144
Lease right-of-use assets
37
31
40
39
26
Goodwill
5
2
2
Long-term investments
41
27
28
Other non-current assets
36
39
27
Total assets
1,832
1,769
1,758
1,316
1,201
Accounts payable
720
617
39
63
48
Accrued liabilities
72
60
103
Short-term debt
3
3
3
18
29
Total current liabilities
804
1,019
1,281
924
914
Long-term debt
237
315
290
Lease liabilities
36
29
34
32
22
Other non-current liabilities
31
18
21
Total liabilities
1,629
1,718
1,942
1,652
1,300
Total debt
316
324
311
333
319
Paid-in capital
7
8
88
90
112
Retained earnings
1,438
1,303
-288
-443
-243
Other comprehensive income
-30
-36
-30
Shareholders' equity
121
-15
-184
-337
-98
Total equity
203
51
0
-337
-98
Total liabilities and equity
1,832
1,769
1,758
1,316
1,201
Cash flow statement
FY2021
FY2023
FY2023
FY2024
FY2025
Net income
205
-44
-126
7
210
Depreciation and amortization
16
15
16
10
Stock-based compensation
16
21
24
26
Deferred income tax
-105
-64
7
-46
Change in receivables
-21
-33
-1
3
Change in inventory
-30
-6
-43
18
Cash from operations
353
-4
-300
36
-27
Capital expenditures
-4
-5
-8
-29
-66
Acquisitions
0
-129
0
0
Cash from investing
-14
-222
-95
69
-66
Debt issued
250
0
0
332
0
Debt repaid
-236
-3
-12
-240
-17
Stock issued
2
3
3
2
Share buybacks
-101
-90
-33
-173
-11
Cash from financing
-94
-101
-64
-102
-30
Exchange rate effect
-1
-1
1
0
Net change in cash
244
-327
-459
3
-124
Free cash flow
349
-9
-308
7
-93
Interest paid
18
18
26
28
34
Income taxes paid
57
32
46
38
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $35.82 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
82.2%
Gross profit / revenue.
Operating margin
31.6%
Operating income / revenue.
EBITDA margin
32.3%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
29.5%
Pre-tax income / revenue.
Net margin
26.7%
Net income / revenue.
FCF margin
-8.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-3.0%
Cash from operations / revenue.
Effective tax rate
9.7%
Income tax / pre-tax income, when pre-tax income is positive.
Return on assets (ROA)
28.9%
Net income / average total assets.
Return on invested capital (ROIC)
667.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
6.2%
Research and development expense / revenue.
SG&A / revenue
44.3%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
2.3%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
5.3%
Capital expenditures / revenue.
D&A / revenue
0.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
4.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
11.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
3.9%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
9.9%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income growth, 1y
589.5%
Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y
403.7%
EBITDA vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
2,900.0%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
3,180.0%
EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
-175.0%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
-1,429.0%
Free cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-8.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-12.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
-3.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-2.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.84x
Current assets / current liabilities.
Quick ratio
0.57x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.26x
(Cash + short-term investments) / current liabilities.
Debt / assets
39.5%
Total debt / total assets.
Liabilities / assets
116.9%
Total liabilities / total assets.
Net debt
$265.0M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA
0.62x
Net debt / EBITDA (twelve months), when EBITDA is positive.
Days inventory + days sales outstanding - days payables.
FCF conversion
-31.2%
Free cash flow / net income, when net income is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$2.87
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$10.73
Revenue / diluted weighted shares.
FCF per share
-$0.90
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.32
Cash from operations / diluted weighted shares.
Book value per share
-$1.68
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
12.6x
Market cap / net income. Only when net income is positive.
P/S
3.36x
Market cap / revenue.
EV/Sales
3.56x
Enterprise value / revenue.
EV/EBIT
11.2x
Enterprise value / operating income, when both are positive.
EV/EBITDA
11.0x
Enterprise value / EBITDA, when both are positive.
FCF yield
-2.5%
Free cash flow / market cap.
Earnings yield
8.0%
Net income / market cap (the inverse of P/E).
Shareholder yield
6.8%
(Dividends paid + share buybacks) / market cap.
What was Indivior Pharmaceuticals, Inc.'s revenue in fiscal 2025?
Indivior Pharmaceuticals, Inc. reported revenue of $1.24B for fiscal 2025, 4.3% higher than the year before.
Was Indivior Pharmaceuticals, Inc. profitable in fiscal 2025?
Yes. Net income was $210.0M, a net margin of 16.9%.
How much free cash flow did Indivior Pharmaceuticals, Inc. generate in fiscal 2025?
Cash from operations of $27.0M minus capital expenditures of $66.0M left free cash flow of -$93.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.